Companies Alignment Healthcare, Inc.
Alignment Healthcare (ALHC): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Alignment Healthcare, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers50th pct.Of 16 peer CEOs
CEO pay, last three years
- $14,296,476FY2023
- $6,369,165FY2024
- $11,278,583FY2025
CEO total pay was $11,278,583 in fiscal 2025, up from $6,369,165 in fiscal 2024.
FY2025: salary $833,654 · bonus $0 · stock awards $8,500,014 · option awards $0
Executives and directors
Dawn Maroney · PresidentChristopher Joyce · General CounselHyong Kim · Chief Medical OfficerJames Head · CFOJohn Kao · CEOThomas Freeman · CFODavid Hodgson · Independent DirectorJacqueline Kosecoff · Independent DirectorJody Bilney · Independent DirectorJoseph Konowiecki · Chair of the BoardMargaret McCarthy · Independent DirectorMark McClellan · Independent DirectorRobbert Vorhoff · Independent DirectorYon Jorden · Independent Director
Frequently asked questions
Who was the highest-paid executive at Alignment Healthcare, Inc. in fiscal 2025?
As disclosed, John Kao (Chief Executive Officer) was the highest-paid executive at Alignment Healthcare, Inc. in fiscal 2025, with total compensation of $11,278,583.
How does Alignment Healthcare, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, John Kao's total compensation ranked at the 50th percentile of Alignment Healthcare, Inc.'s disclosed peer group.
What is Alignment Healthcare, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Alignment Healthcare, Inc.'s CEO-to-median employee pay ratio was 158:1.
How did shareholders vote on Alignment Healthcare, Inc.'s executive compensation?
As disclosed, 94.82% of shareholders supported Alignment Healthcare, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Alignment Healthcare, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Alignment Healthcare, Inc. reported total board compensation of $2,700,000 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Kao | $833,654 | $0 | $8,500,014 | $0 | $1,944,495 | $0 | $420 | $11,278,583 |
| Chief Executive Officer | ||||||||
| Dawn Maroney | 676,923 | 0 | 3,700,006 | 0 | 1,053,483 | 0 | 14,420 | 5,444,832 |
| President | ||||||||
| James Head | 394,616 | 0 | 2,500,010 | 0 | 429,302 | 0 | 1,908 | 3,325,835 |
| Chief Financial Officer | ||||||||
| Hyong Kim | 560,000 | 0 | 1,800,016 | 0 | 754,585 | 0 | 14,420 | 3,129,021 |
| Chief Medical Officer | ||||||||
| Christopher Joyce | 525,000 | 0 | 1,750,012 | 0 | 760,435 | 0 | 14,000 | 3,049,447 |
| Chief Legal & Administrative Officer | ||||||||
| Thomas Freeman | 501,923 | 0 | 1,899,990 | 0 | 476,673 | 0 | 8,215 | 2,886,811 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Kao | $11,278,583 | $6,369,165 | $14,296,476 | ↑ +4,909,418 |
| Dawn Maroney | 5,444,832 | 3,083,284 | 6,458,999 | ↑ +2,361,548 |
| James Head | 3,325,835 | — | — | — |
| Hyong Kim | 3,129,021 | 2,478,072 | 3,059,277 | ↑ +650,949 |
| Christopher Joyce | 3,049,447 | — | — | — |
| Thomas Freeman | 2,886,811 | 2,848,490 | 6,302,045 | ↑ +38,321 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Thomas Freeman | PSU | 2025-03-13 | 30,645 | 61,290 | — | 122,580 | $949,995 |
| Dawn Maroney | PSU | 2025-03-13 | 59,678 | 119,355 | — | 238,710 | 1,850,003 |
| James Head | RSU | 2025-06-04 | — | — | 81,593 | — | 1,250,005 |
| James Head | PSU | 2025-06-04 | 40,797 | 81,593 | — | 163,186 | 1,250,005 |
| Christopher Joyce | RSU | 2025-03-13 | — | — | 56,452 | — | 875,006 |
| Christopher Joyce | PSU | 2025-03-13 | 28,226 | 56,452 | — | 112,904 | 875,006 |
| Hyong Kim | RSU | 2025-03-13 | — | — | 58,065 | — | 900,008 |
| Thomas Freeman | RSU | 2025-03-13 | — | — | 61,290 | — | 949,995 |
| John Kao | PSU | 2025-03-13 | 137,097 | 274,194 | — | 548,388 | 4,250,007 |
| John Kao | RSU | 2025-03-13 | — | — | 274,194 | — | 4,250,007 |
| Hyong Kim | PSU | 2025-03-13 | 29,033 | 58,065 | — | 116,130 | 900,008 |
| Dawn Maroney | RSU | 2025-03-13 | — | — | 119,355 | — | 1,850,003 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Thomas Freeman | $949,995 | $949,995 | $0 | 50.0% |
| Dawn Maroney | 1,850,003 | 1,850,003 | 0 | 50.0% |
| James Head | 1,250,005 | 1,250,005 | 0 | 50.0% |
| Christopher Joyce | 875,006 | 875,006 | 0 | 50.0% |
| Hyong Kim | 900,008 | 900,008 | 0 | 50.0% |
| John Kao | 4,250,007 | 4,250,007 | 0 | 50.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Dawn Maroney | Option | 38,017 | 9.06 | — |
| Thomas Freeman | PSU | 40,860 | — | 806,985 |
| Dawn Maroney | RSU | 51,738 | — | 1,021,826 |
| Thomas Freeman | RSU | 55,000 | — | 1,086,250 |
| Christopher Joyce | PSU | 56,452 | — | 1,114,927 |
| Hyong Kim | PSU | 58,065 | — | 1,146,784 |
| Thomas Freeman | PSU | 61,290 | — | 1,210,478 |
| James Head | PSU | 81,593 | — | 1,611,462 |
| John Kao | Option | 91,241 | 9.06 | — |
| Dawn Maroney | RSU | 97,500 | — | 1,925,625 |
| Christopher Joyce | RSU | 97,500 | — | 1,925,625 |
| Hyong Kim | PSU | 105,000 | — | 2,073,750 |
| Thomas Freeman | PSU | 110,000 | — | 2,172,500 |
| Dawn Maroney | PSU | 119,355 | — | 2,357,261 |
| Christopher Joyce | RSU | 122,511 | — | 2,419,592 |
| John Kao | PSU | 124,172 | — | 2,452,397 |
| Dawn Maroney | PSU | 130,000 | — | 2,567,500 |
| Christopher Joyce | PSU | 130,000 | — | 2,567,500 |
| Hyong Kim | PSU | 140,000 | — | 2,765,000 |
| Hyong Kim | RSU | 170,068 | — | 3,358,843 |
| Dawn Maroney | PSU | 215,661 | — | 4,259,305 |
| John Kao | RSU | 247,500 | — | 4,888,125 |
| John Kao | PSU | 274,194 | — | 5,415,332 |
| John Kao | PSU | 330,000 | — | 6,517,500 |
| John Kao | PSU | 819,513 | — | 16,185,382 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Joseph KonowieckiNot independent · Board Chair · Compensation | $100,000 | $390,000 | $0 | $0 | $0 | $490,000 |
| Margaret McCarthyIndependent · Audit Committee · Compensation Committee | 145,000 | 210,000 | 0 | 0 | 0 | 355,000 |
| Jacqueline KosecoffIndependent · Compensation Committee (Chair) · NCGCC | 132,500 | 190,000 | 0 | 0 | 0 | 322,500 |
| Yon JordenIndependent · Audit (Chair) · Compensation | 130,000 | 190,000 | 0 | 0 | 0 | 320,000 |
| David HodgsonIndependent · NCGCC (Chair) | 20,000 | 290,000 | 0 | 0 | 0 | 310,000 |
| Jody BilneyIndependent · Audit Committee | 65,000 | 240,000 | 0 | 0 | 0 | 305,000 |
| Robbert VorhoffIndependent · Compensation Committee | 10,000 | 290,000 | 0 | 0 | 0 | 300,000 |
| Mark McClellanIndependent · NCGCC | 107,500 | 190,000 | 0 | 0 | 0 | 297,500 |
| John KaoEmployee director · Compensation | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $0 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 20,000 |
| Stock ownership guideline | $500,000 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $710,000 |
| Equity awards (grant-date value) | $1,990,000 |
| All other compensation | $0 |
| Total cost of the board | $2,700,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Alignment Healthcare as a peer
Companies that benchmark against ALHC
9 companies name ALHC as a compensation peer
The list of companies that name ALHC as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
EVH Evolent Health, Inc.CLOV Clover Health Investments Corp.RDNT RadNet, Inc.OSCR Oscar Health, Inc.AHCO AdaptHealth Corp.OPCH Option Care Health, Inc.AGL agilon health, inc.ASTH Astrana Health, Inc.MD Pediatrix Medical Group, Inc.BLCO Bausch & Lomb Corp.PRVA Privia Health Group, Inc.DGX Quest Diagnostics Inc.DVA DaVita Inc.ENSG Ensign Group, Inc.SEM Select Medical Holdings Corp.TDOC Teladoc Health, Inc.
Peer reciprocity
Of the companies Alignment Healthcare, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
— Evolent Health, Inc. (EVH)82— Clover Health Investments Corp. (CLOV)83— RadNet, Inc. (RDNT)84— Oscar Health, Inc. (OSCR)85✓ AdaptHealth Corp. (AHCO)86— Option Care Health, Inc. (OPCH)87✓ agilon health, inc. (AGL)88 Astrana Health, Inc. (ASTH) Pediatrix Medical Group, Inc. (MD)— Bausch & Lomb Corp. (BLCO)89✓ Privia Health Group, Inc. (PRVA)90— Quest Diagnostics Inc. (DGX)91— DaVita Inc. (DVA)92— Ensign Group, Inc. (ENSG)93 Select Medical Holdings Corp. (SEM)✓ Teladoc Health, Inc. (TDOC)94
Reciprocity shown where the peer’s own current proxy has been read — each mark is cited in the register to that peer’s filing. A dash means the peer’s current proxy was read and names no reciprocal group including Alignment Healthcare, Inc..
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Bausch & Lomb Corp. | 2025 | Brenton Saunders | $1,600,000 | $23,778,578 | $2,799,998 | $4,000,000 | $32,194,326 |
| 2 | DaVita Inc. | 2025 | Javier Rodriguez | 1,500,000 | 11,442,481 | 2,699,982 | 2,089,491 | 18,210,597 |
| 3 | Quest Diagnostics Inc. | 2025 | James Davis | 1,250,000 | 8,762,861 | 2,999,873 | 2,205,844 | 15,498,479 |
| 4 | Astrana Health, Inc. | 2025 | Brandon Sim | 850,000 | 11,999,980 | 0 | 2,059,125 | 14,930,231 |
| 5 | Evolent Health, Inc. | 2025 | Seth Blackley | 867,068 | 12,699,086 | 0 | 0 | 14,240,154 |
| 6 | Pediatrix Medical Group, Inc. | 2025 | Mark Ordan | 970,014 | 8,456,024 | 0 | 2,700,000 | 14,140,217 |
| 7 | Ensign Group, Inc. | 2025 | Barry Port | 549,264 | 2,912,355 | 0 | 10,317,247 | 13,804,700 |
| 8 | RadNet, Inc. | 2025 | Howard Berger | 3,000,000 | 8,999,966 | 0 | 0 | 12,087,934 |
| 9 | Alignment Healthcare, Inc. | 2025 | John Kao | 833,654 | 8,500,014 | 0 | 1,944,495 | 11,278,583 |
| 10 | Teladoc Health, Inc. | 2025 | Charles Divita, III | 800,000 | 9,699,996 | 0 | 584,000 | 11,202,996 |
| 11 | Privia Health Group, Inc. | 2025 | Parth Mehrotra | 650,000 | 8,588,373 | 0 | 1,218,750 | 10,472,698 |
| 12 | AdaptHealth Corp. | 2025 | Suzanne Foster | 1,000,000 | 7,530,880 | 0 | 1,394,694 | 10,256,240 |
| 13 | Option Care Health, Inc. | 2025 | John Rademacher | 1,000,000 | 6,500,050 | 0 | 1,665,000 | 9,266,330 |
| 14 | agilon health, inc. | 2025 | Jeffrey Schwaneke | 625,000 | 2,950,003 | 1,750,000 | 271,875 | 5,610,878 |
| 15 | Select Medical Holdings Corp. | 2025 | Thomas Mullin | 618,000 | 1,425,000 | 0 | 939,360 | 3,042,527 |
| 16 | Clover Health Investments Corp. | 2025 | Andrew Toy | 800,000 | 0 | 0 | 509,539 | 1,319,385 |
| 17 | Oscar Health, Inc. | 2025 | Mark Bertolini | 619,178 | 0 | 0 | 169,036 | 1,149,308 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Alignment Healthcare, Inc. | 200% | not disclosed | No | FW Cook |
| AdaptHealth Corp. | 116.22% | PSU 50 · RSU 50 | Yes — Relative TSR | ClearBridge |
| agilon health, inc. | 58% | not disclosed | No | Semler Brossy |
| Astrana Health, Inc. | 193.8% | PSU 67 · RSU 33 | No | Pearl Meyer |
| Bausch & Lomb Corp. | 100% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pay Governance |
| Clover Health Investments Corp. | 64% | RSU 60 · Cash LTI 40 | No | Aon, plc (Human Capital Practice) |
| DaVita Inc. | 93% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR v. S&P Health Care Services Select Industry Index | Compensia |
| Ensign Group, Inc. | not disclosed | not disclosed | not disclosed | Willis Towers Watson |
| Evolent Health, Inc. | 75% | PSU 70 · RSU 30 | No | Exequity |
| Option Care Health, Inc. | 111% | PSU 60 · RSU 40 | No | Pearl Meyer |
| Oscar Health, Inc. | 91.0% | RSU 50 · PSU 50 | Yes — Relative TSR | FW Cook |
| Pediatrix Medical Group, Inc. | 180% | RSU 50 · PSU 50 | No | Semler Brossy Consulting Group |
| Privia Health Group, Inc. | 150% | PSU 60 · RSU 40 | No | Korn Ferry (through September 2025), WTW (starting September 2025) |
| Quest Diagnostics Inc. | 113.9% | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | Semler Brossy |
| RadNet, Inc. | not disclosed | RSU 100 | No | Pearl Meyer |
| Select Medical Holdings Corp. | 190% | RSU 100 | not disclosed | not disclosed |
| Teladoc Health, Inc. | 73% | RSU 50 · PSU 50 | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 169,068,300 | 8,701,941 | 542,191 | 94.82% | Passed |
| 2025 | 2025-06-05 | 162,732,057 | 1,840,930 | 494,523 | 98.59% | Passed |
| 2024 | 2024-06-07 | 138,403,746 | 21,289,607 | 5,882 | 86.67% | Passed |
| 2023 | 2023-06-06 | 110,852,417 | 54,729,829 | 277,422 | 66.84% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 94.82%a |
| 2025 | 2025-06-05 | 98.59%b |
| 2024 | 2024-06-07 | 86.67%c |
a. Approved under the standard stated in the filing — “(4) Abstentions will be counted as present and entitled to vote on the proposals and will therefore have the effect of a negative vote.”.
b. Approved under the standard stated in the filing — “(4) Abstentions will be counted as present and entitled to vote on the proposals and will therefore have the effect of a negative vote.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted as present and entitled to vote on the proposals and will therefore have the effect of a negative vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 158 : 1 |
|---|---|
| CEO total compensation | $11,278,583 |
| Median employee compensation | $71,260 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John Kao | Director | 2026-05-11 | D | 17,107 | $18 | $299,971 | Common | Form 4 ↗ |
| John Kao | Director | 2026-05-11 | D | 280,893 | 17 | 4,732,879 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-05-15 | D | 1,500 | 0 | 0 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-05-15 | D | 30,000 | 16 | 482,565 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-05-18 | D | 20,000 | 0 | 0 | Common | Form 4 ↗ |
| Mark D. Kent | President - MSO | 2026-06-02 | A | 14,848 | 13 | 197,627 | Common | Form 4 ↗ |
| Mark D. Kent | President - MSO | 2026-06-03 | A | 87,719 | 0 | 0 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-06-03 | A | 122,807 | 0 | 0 | Common | Form 4 ↗ |
| John Kao | Director | 2026-06-10 | D | 223,064 | 21 | 4,594,271 | Common | Form 4 ↗ |
| John Kao | Director | 2026-06-10 | D | 74,936 | 20 | 1,472,350 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-06-11 | D | 25,000 | 21 | 525,000 | Common | Form 4 ↗ |
| Hyong Kim | Chief Medical Officer | 2026-06-12 | D | 35,951 | 20 | 713,947 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-06-15 | D | 30,000 | 20 | 586,425 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-06-18 | D | 25,000 | 22 | 550,000 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-06-26 | D | 25,000 | 23 | 575,000 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-07-01 | D | 25,000 | 24 | 600,000 | Common | Form 4 ↗ |
| Shane J. Hochradel | Chief Operations Officer | 2026-07-01 | A | 87,719 | 0 | 0 | Common | Form 4 ↗ |
| John Kao | Director | 2026-07-10 | D | 18,356 | 21 | 378,998 | Common | Form 4 ↗ |
| John Kao | Director | 2026-07-10 | D | 279,644 | 20 | 5,540,363 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-07-15 | D | 177,068 | 21 | 3,687,990 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-07-15 | A | 152,068 | 9 | 1,377,736 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-07-15 | D | 152,068 | 9 | 1,377,736 | Derivative, Class A Common | Form 4 ↗ |
| John Kao | Director | 2026-08-10 | D | 298,000 | 14 | 4,136,776 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-08-14 | D | 5,000 | 14 | 70,000 | Common | Form 4 ↗ |
| John Kao | Director | 2026-09-10 | D | 172,600 | 13 | 2,236,447 | Common | Form 4 ↗ |
| Dawn Maroney | President | 2026-09-11 | D | 122,707 | 13 | 1,555,925 | Common | Form 4 ↗ |
| John Kao | Director | 2026-09-11 | D | 385,270 | 13 | 4,885,224 | Common | Form 4 ↗ |
| John Kao | Director | 2026-09-14 | D | 27,400 | 13 | 356,200 | Common | Form 4 ↗ |
| Joseph Konowiecki | Director | 2026-09-17 | D | 23,511 | 9 | 202,430 | Common | Form 4 ↗ |
| Hyong Kim | Chief Medical Officer | 2026-10-06 | D | 32,479 | 8 | 269,576 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (94 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, John Kao. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · page 57. As printed: 11,278,583. View filing ↗
- Section 01, Dawn Maroney. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 5,444,832. View filing ↗
- Section 01, James Head. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 3,325,835. View filing ↗
- Section 01, Hyong Kim. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 3,129,021. View filing ↗
- Section 01, Christopher Joyce. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 3,049,447. View filing ↗
- Section 01, Thomas Freeman. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 2,886,811. View filing ↗
- Section 03, Thomas Freeman PSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Dawn Maroney PSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, James Head RSU. DEF 14A. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, James Head PSU. DEF 14A. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Joyce RSU. DEF 14A, filed 2026-04-24. Section “EACH OF THE ABOVE DIRECTOR NOMINEES.” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Joyce PSU. DEF 14A, filed 2026-04-24. Section “EACH OF THE ABOVE DIRECTOR NOMINEES.” · grants of plan-based awards table. View filing ↗
- Section 03, Hyong Kim RSU. DEF 14A, filed 2026-04-24. Section “EACH OF THE ABOVE DIRECTOR NOMINEES.” · grants of plan-based awards table. View filing ↗
- Section 03, Thomas Freeman RSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, John Kao PSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, John Kao RSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Hyong Kim PSU. DEF 14A, filed 2026-04-24. Section “EACH OF THE ABOVE DIRECTOR NOMINEES.” · grants of plan-based awards table. View filing ↗
- Section 03, Dawn Maroney RSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-24. Section “CEO Pay Ratio”. As printed: 158 : 1. View filing ↗
- Section 08, Joseph Konowiecki. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 490,000. View filing ↗
- Section 08, Margaret McCarthy. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 355,000. View filing ↗
- Section 08, Jacqueline Kosecoff. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 322,500. View filing ↗
- Section 08, Yon Jorden. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 320,000. View filing ↗
- Section 08, David Hodgson. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 310,000. View filing ↗
- Section 08, Jody Bilney. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 305,000. View filing ↗
- Section 08, Robbert Vorhoff. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 300,000. View filing ↗
- Section 08, Mark McClellan. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 297,500. View filing ↗
- Section 08, John Kao. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, John Kao 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kao 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Maroney 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Maroney 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Maroney 2026-05-18. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark D. Kent 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark D. Kent 2026-06-03. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Konowiecki 2026-06-03. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kao 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kao 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Konowiecki 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hyong Kim 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Maroney 2026-06-15. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Konowiecki 2026-06-18. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Konowiecki 2026-06-26. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Konowiecki 2026-07-01. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane J. Hochradel 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kao 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kao 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Maroney 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Maroney 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Maroney 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kao 2026-08-10. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Maroney 2026-08-14. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kao 2026-09-10. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dawn Maroney 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kao 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kao 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph Konowiecki 2026-09-17. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hyong Kim 2026-10-06. Form 4, filed 2026-10-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-09. Item 5.07 · say-on-pay result. As reported: 94.82% (votes for as printed: 169,068,300). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-11. Item 5.07 · say-on-pay result. As reported: 98.59% (votes for as printed: 162,732,057). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-13. Item 5.07 · say-on-pay result. As reported: 86.67% (votes for as printed: 138,403,746). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 710,000 + equity 1,990,000 + all other 0 = 2,700,000, summed across the director compensation table rows.
- Bausch & Lomb Corp., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Bausch & Lomb Corp.'s own proxy. As printed: 32,194,326. View filing ↗
- DaVita Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in DaVita Inc.'s own proxy. As printed: 18,210,597. View filing ↗
- Quest Diagnostics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Quest Diagnostics Inc.'s own proxy. As printed: 15,498,479. View filing ↗
- Astrana Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Astrana Health, Inc.'s own proxy. As printed: 14,930,231. View filing ↗
- Evolent Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Evolent Health, Inc.'s own proxy. As printed: 14,240,154. View filing ↗
- Pediatrix Medical Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Pediatrix Medical Group, Inc.'s own proxy. As printed: 14,140,217. View filing ↗
- Ensign Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Ensign Group, Inc.'s own proxy. As printed: 13,804,700. View filing ↗
- RadNet, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in RadNet, Inc.'s own proxy. As printed: 12,087,934. View filing ↗
- Alignment Healthcare, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Alignment Healthcare, Inc.'s own proxy. As printed: 11,278,583. View filing ↗
- Teladoc Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Teladoc Health, Inc.'s own proxy. As printed: 11,202,996. View filing ↗
- Privia Health Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Privia Health Group, Inc.'s own proxy. As printed: 10,472,698. View filing ↗
- AdaptHealth Corp., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in AdaptHealth Corp.'s own proxy. As printed: 10,256,240. View filing ↗
- Option Care Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Option Care Health, Inc.'s own proxy. As printed: 9,266,330. View filing ↗
- agilon health, inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in agilon health, inc.'s own proxy. As printed: 5,610,878. View filing ↗
- Select Medical Holdings Corp., Section 10b CEO total. DEF 14A, filed 2026-03-04. CEO total compensation as printed in Select Medical Holdings Corp.'s own proxy. As printed: 3,042,527. View filing ↗
- Clover Health Investments Corp., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Clover Health Investments Corp.'s own proxy. As printed: 1,319,385. View filing ↗
- Oscar Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Oscar Health, Inc.'s own proxy. As printed: 1,149,308. View filing ↗
- Section 10a, Evolent Health, Inc. reciprocity. DEF 14A. Evolent Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare, Inc.. View filing ↗
- Section 10a, Clover Health Investments Corp. reciprocity. DEF 14A. Clover Health Investments Corp.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare, Inc.. View filing ↗
- Section 10a, RadNet, Inc. reciprocity. DEF 14A. RadNet, Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare, Inc.. View filing ↗
- Section 10a, Oscar Health, Inc. reciprocity. DEF 14A. Oscar Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare, Inc.. View filing ↗
- Section 10a, AdaptHealth Corp. reciprocity. DEF 14A. AdaptHealth Corp. names Alignment Healthcare, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Option Care Health, Inc. reciprocity. DEF 14A. Option Care Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare, Inc.. View filing ↗
- Section 10a, agilon health, inc. reciprocity. DEF 14A. agilon health, inc. names Alignment Healthcare, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Bausch & Lomb Corp. reciprocity. DEF 14A. Bausch & Lomb Corp.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare, Inc.. View filing ↗
- Section 10a, Privia Health Group, Inc. reciprocity. DEF 14A. Privia Health Group, Inc. names Alignment Healthcare, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Quest Diagnostics Inc. reciprocity. DEF 14A. Quest Diagnostics Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare, Inc.. View filing ↗
- Section 10a, DaVita Inc. reciprocity. DEF 14A. DaVita Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare, Inc.. View filing ↗
- Section 10a, Ensign Group, Inc. reciprocity. DEF 14A. Ensign Group, Inc.'s most recent proxy was read; its disclosed peer group does not include Alignment Healthcare, Inc.. View filing ↗
- Section 10a, Teladoc Health, Inc. reciprocity. DEF 14A. Teladoc Health, Inc. names Alignment Healthcare, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗